Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 1;1638(Pt A):88-96.
doi: 10.1016/j.brainres.2015.06.053. Epub 2015 Jul 31.

Regenerative cellular therapies for neurologic diseases

Michael Levy  1 , Nicholas Boulis  2 , Mahendra Rao  3 , Clive N Svendsen  4
Affiliations
Review

Regenerative cellular therapies for neurologic diseases

Michael Levy et al. Brain Res. .

Abstract

The promise of stem cell regeneration has been the hope of many neurologic patients with permanent damage to the central nervous system. There are hundreds of stem cell trials worldwide intending to test the regenerative capacity of stem cells in various neurological conditions from Parkinson's disease to multiple sclerosis. Although no stem cell therapy is clinically approved for use in any human disease indication, patients are seeking out trials and asking clinicians for guidance. This review summarizes the current state of regenerative stem cell transplantation divided into seven conditions for which trials are currently active: demyelinating diseases/spinal cord injury, amyotrophic lateral sclerosis, stroke, Parkinson's disease, Huntington's disease, macular degeneration and peripheral nerve diseases. This article is part of a Special Issue entitled SI: PSC and the brain.

Keywords: Neurologic disease; Regeneration; Stem cell.

PubMed Disclaimer

References

    1. Bar-Or M-N, Boivin A, Rozenberg A, Johnson T, Belabani C, Morisse G, Sirois J, Lai Wing Sun S, Vanamala S, Del Rosario Villalobos A, Reese Koc J, Morrison S, Bermel RA, Imrey PB, Planchon SM, Cohen JA. Immune function monitoring in a phase I trial of autologous culture-expanded mesenchymal stem cell transplantation for relapsing multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis Meeting; Boston, MA. 2014.
    1. Ambasudhan R, Dolatabadi N, Nutter A, Masliah E, McKercher SR, Lipton SA. Potential for cell therapy in Parkinson’s disease using genetically programmed human embryonic stem cell-derived neural progenitor cells. The Journal of comparative neurology. 2014;522(12):2845–56. - PMC - PubMed
    1. Andres RH, Horie N, Slikker W, Keren-Gill H, Zhan K, Sun G, et al. Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain: a journal of neurology. 2011;134(Pt 6):1777–89. - PMC - PubMed
    1. Aquino JB, Hjerling-Leffler J, Koltzenburg M, Edlund T, Villar MJ, Ernfors P. In vitro and in vivo differentiation of boundary cap neural crest stem cells into mature Schwann cells. Experimental neurology. 2006;198(2):438–49. - PubMed
    1. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(43):16707–12. - PMC - PubMed

Publication types

MeSH terms